155 related articles for article (PubMed ID: 37349100)
1. Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol.
Justesen TF; Gögenur I; Tarpgaard LS; Pfeiffer P; Qvortrup C
BMJ Open; 2023 Jun; 13(6):e073372. PubMed ID: 37349100
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
[TBL] [Abstract][Full Text] [Related]
3. Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial.
Chen X; Leng W; Zhou Y; Yu Y; Meng W; Cao P; Wang Z; Qiu M
BMJ Open; 2023 Jan; 13(1):e062659. PubMed ID: 36720570
[TBL] [Abstract][Full Text] [Related]
4. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
[TBL] [Abstract][Full Text] [Related]
5. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
[TBL] [Abstract][Full Text] [Related]
6. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
[TBL] [Abstract][Full Text] [Related]
7. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
8. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial.
Liu F; Tong T; Huang D; Yuan W; Li D; Lin J; Cai S; Xu Y; Chen W; Sun Y; Zhuang J
BMJ Open; 2019 Jan; 9(1):e017637. PubMed ID: 30700474
[TBL] [Abstract][Full Text] [Related]
9. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
[No Abstract] [Full Text] [Related]
10. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).
Rovers KP; Lurvink RJ; Wassenaar EC; Kootstra TJ; Scholten HJ; Tajzai R; Deenen MJ; Nederend J; Lahaye MJ; Huysentruyt CJ; van 't Erve I; Fijneman RJ; Constantinides A; Kranenburg O; Los M; Thijs AM; Creemers GM; Burger JW; Wiezer MJ; Boerma D; Nienhuijs SW; de Hingh IH
BMJ Open; 2019 Jul; 9(7):e030408. PubMed ID: 31352425
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
12. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
14. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
Veen T; Kanani A; Lea D; Søreide K
Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
19. Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
Eefsen RL; Larsen JS; Klarskov LL; Altaf R; Høgdall E; Ingeholm P; Lykke J; Nielsen DL; Pfeiffer P; Poulsen LØ; Qvortrup C; Schou JV; Mau-Sørensen M; Østerlind K; Jensen BV
Int J Cancer; 2023 May; 152(10):2145-2152. PubMed ID: 36594580
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
